Sun Pharmaceutical Industries Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Revital

Volini

Abzorb

Pepfiz

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Sun Pharmaceutical Industries is experiencing a bullish reversal, trading near ₹1799.40. The stock has broken above its trendline and found support at key moving averages, indicating strong demand. The RSI suggests healthy momentum, while ₹1747 remains a critical support level.

Sun Pharma Shows Strong Bullish Reversal Signs - 07 Mar, 2026

Goldman Sachs has issued a 'Sell' rating on Sun Pharmaceutical Industries Ltd, setting a target price of Rs 1550 for the stock.

Goldman Sachs Recommends Sell on Sun Pharma - 05 Mar, 2026

Sun Pharmaceutical Industries has received DCGI approval to manufacture and market generic semaglutide injection. The drug will be marketed under two brands for weight management and Type 2 diabetes after patent expiry.

Sun Pharma Gains Approval for Generic Semaglutide Injection - 26 Feb, 2026

Dilip Shanghvi, Executive Chairman of Sun Pharmaceutical Industries, emphasized the industry's manufacturing strength and growing customer confidence in global generics, while calling for innovation.

Sun Pharma's Chairman Highlights Industry Strengths - 24 Feb, 2026

On February 9, 2026, SUN PHARMA's stock showed stable performance with modest changes, primarily positive or flat, amidst broader market trends.

SUNPHARMA Shows Stable Performance Amid Market Changes - 09 Feb, 2026

Sun Pharmaceutical Industries reported flat performance in the US market, with growth in innovative medicines offset by generics decline. Chairman Dilip Shanghvi stressed the importance of innovation and a disciplined approach to M&A for sustainable growth.

Sun Pharma Reports Flat Growth, Emphasizes Innovation - 08 Feb, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 7 days, SUNPHARMA stock has moved up by 2.7%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Revenue is up for the last 4 quarters, 13.57K Cr → 16.09K Cr (in ₹), with an average increase of 5.5% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Netprofit is up for the last 4 quarters, 2.14K Cr → 3.36K Cr (in ₹), with an average increase of 13.3% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

In the last 3 years, Torrent Pharmaceuticals Ltd has given 185.3% return, outperforming this stock by 97.3%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Promoters holdings remained unchanged at 54.48% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 1 year, Torrent Pharmaceuticals Ltd has given 40.6% return, outperforming this stock by 28.9%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Mutual Funds have decreased holdings from 12.41% to 12.09% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Retail Investor have decreased holdings from 8.73% to 8.58% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Foreign Institutions have decreased holdings from 16.55% to 16.12% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Nifty100 Low Volatility 30

BSE Healthcare

BSE 100

Nifty 200

Nifty100 Eq Weig

NIFTY 100

S&P BSE 100 LargeCap TMC

S&P BSE 100 ESG

S&P BSE Dividend Stability

S&P BSE Low Volatility

S&P BSE SENSEX 50

BSE 200

BSE MFG

NIFTY PHARMA

Nifty Healthcare

Nifty LargeMidcap 250

SENSEX

Nifty 500

S&P BSE 250 LargeMidCap

NIFTY 50

BSE 500

ICICI Prudential Value Fund Direct Plan Growth

ICICI Prudential Equity & Debt Fund Direct Plan Growth

ICICI Prudential Large Cap Fund Direct Plan Growth

HDFC Balanced Advantage Fund Direct Plan Growth Option

ICICI Prudential India Opportunities Fund Direct Growth

Sun Pharma shows strong bullish breakout with a 3.5% weekly gain, supported by increased volumes and positive indicators.

Sun Pharmaceutical Industries Ltd’s net profit jumped 16.03% since last year same period to ₹3,368.81Cr in the Q3 2025-2026. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated 8.05% jump in its net profits since last 3-months.

Sun Pharmaceutical Industries Ltd Earnings Results

In the quarter ending December 2025, Sun Pharmaceutical Industries Ltd has declared dividend of ₹11.00 per share on 31 Jan 2026 - translating a dividend yield of 1.51%.

Name	Value	Action
MACD level (12,26)	-1.55	Bearish
CCI (20)	-209.96	Bullish
RSI (14)	31	Neutral
Momentum (10)	-6.9	Bearish
ADI (14)	51.78	Bearish
Ultimate Oscillator (7,14,28)	63.36	Neutral

Name	Value	Action
SMA (20)	1799.07	Bearish
EMA (20)	1798.05	Bearish
VWMA (20)	1797.74	Bearish
SMA (50)	1800.1	Bearish
EMA (50)	1799.58	Bearish
SMA (200)	1800.65	Bearish
EMA (200)	1798.61	Bearish
KAMA (200)	1800.13	Bearish
DEMA (200)	1802.75	Bearish

Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Summary

Overall

Oscillators

Moving Averages